{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T08:55:44Z","timestamp":1784796944731,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.therap.2024.03.002","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T13:22:30Z","timestamp":1711632150000},"page":"680-691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of the vaccination against SARS-CoV-2 campaign on disproportionality indicator from the WHO pharmacovigilance database: A competition bias study from case\/non-case analysis"],"prefix":"10.1016","volume":"79","author":[{"given":"Francis","family":"Adja\u00ef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorine","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Dolladille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Lebrun-Vignes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Bihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2024.03.002_bib0115","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/pds.1058","article-title":"The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions","volume":"14","author":"Moore","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2024.03.002_bib0120","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.therap.2019.09.004","article-title":"Pharmacovigilance\u00a0\u2013\u00a0the next chapter","volume":"74","author":"Moore","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.03.002_bib0125","doi-asserted-by":"crossref","unstructured":"Bate A., Lindquist M., Edwards I.R., Olsson S., Orre R., Lansner A., et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998;54:315\u2013321. https:\/\/pubmed.ncbi.nlm.nih.gov\/9696956\/. [Accessed 22 March 2024]","DOI":"10.1007\/s002280050466"},{"key":"10.1016\/j.therap.2024.03.002_bib0130","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.therap.2020.02.022","article-title":"Uses of pharmacovigilance databases: an overview","volume":"75","author":"Bihan","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.03.002_bib0135","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40264-013-0063-5","article-title":"A potential event-competition bias in safety signal detection: results from a spontaneous reporting research database in France","volume":"36","author":"Salvo","year":"2013","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2024.03.002_bib0140","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/pds.2022","article-title":"A potential competition bias in the detection of safety signals from spontaneous reporting databases","volume":"19","author":"Pariente","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2024.03.002_bib0145","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case-non-case studies: principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.03.002_bib0150","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/BF03261981","article-title":"Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France","volume":"35","author":"Pariente","year":"2012","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2024.03.002_bib0155","series-title":"Vigibase","year":"2024"},{"key":"10.1016\/j.therap.2024.03.002_bib0160","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/pds.3474","article-title":"Outlier removal to uncover patterns in adverse drug reaction surveillance\u00a0\u2013\u00a0a simple unmasking strategy","volume":"22","author":"Juhlin","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2024.03.002_bib0165","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s40264-022-01186-z","article-title":"Signaling COVID-19 vaccine adverse events","volume":"45","author":"Harpaz","year":"2022","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2024.03.002_bib0170","series-title":"VigiBase: WHO's global database signalling harm and pointing to safer use","year":"2024"},{"key":"10.1016\/j.therap.2024.03.002_bib0175","series-title":"History","year":"2024"},{"key":"10.1016\/j.therap.2024.03.002_bib0180","series-title":"Selected adverse events reported after COVID-19 vaccination","year":"2023"},{"key":"10.1016\/j.therap.2024.03.002_bib0185","series-title":"European database of suspected adverse drug reactions report","year":"2024"},{"key":"10.1016\/j.therap.2024.03.002_bib0190","series-title":"Health","year":"2024"},{"key":"10.1016\/j.therap.2024.03.002_bib0195","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von\u00a0Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.therap.2024.03.002_bib0200","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s40264-023-01346-9","article-title":"An exploratory study of the impact of COVID-19 vaccine spontaneous reporting on masking signal detection in EudraVigilance","volume":"46","author":"Micallef","year":"2023","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2024.03.002_bib0205","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/pds.4682","article-title":"Impact of the \u201cFrench Levothyrox crisis\u201d on signal detection in the World Health Organization pharmacovigilance database","volume":"27","author":"Khouri","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2024.03.002_bib0210","series-title":"Unmasking data in the COVID-19 era","year":"2022"},{"key":"10.1016\/j.therap.2024.03.002_bib0215","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jclinepi.2023.08.010","article-title":"Pharmacovigilance studies without a priori hypothesis systematic review highlights inappropriate multiple testing correction procedures","volume":"162","author":"Gaucher","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.therap.2024.03.002_bib0220","doi-asserted-by":"crossref","first-page":"727687","DOI":"10.3389\/fpsyt.2021.727687","article-title":"Risk of bleeding associated with antidepressants: impact of causality assessment and competition bias on signal detection","volume":"12","author":"Zeiss","year":"2021","journal-title":"Front Psychiatry"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724000398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724000398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T13:54:50Z","timestamp":1732370090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595724000398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0040595724000398"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2024.03.002","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of the vaccination against SARS-CoV-2 campaign on disproportionality indicator from the WHO pharmacovigilance database: A competition bias study from case\/non-case analysis","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2024.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}